Drug
Dalpiciclib clinical trials
Also written SHR6390.
- studies test it
- 67
- open now
- 35
- in phase 3
- 7
- first study started
- 2016
Keep track of what changes. Save the dalpiciclib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- SHR6390
- 28
Studies by the year they started
67 studies that test it; most in 2022 (15)
| Year | Studies |
|---|---|
| 2016 | 2 |
| 2018 | 3 |
| 2019 | 4 |
| 2020 | 9 |
| 2021 | 4 |
| 2022 | 15 |
| 2023 | 8 |
| 2024 | 6 |
| 2025 | 8 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 19
- Phase 2
- 42
- Phase 3
- 7
- Phase 4
- 1
- No phase
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 54
Jiangsu HengRui Medicine Co., Ltd. (11) · Fudan University (10) · Shengjing Hospital (4) · Tianjin Medical University Cancer Institute and Hospital (4) · Peking University (3) · Henan Cancer Hospital (3) · Fujian Cancer Hospital (3) · Beijing 302 Hospital (2)
Often tested with
Tested in the same studies.
Pyrotinib (12) · Letrozole (7) · Fulvestrant (6) · Trastuzumab (6) · Camrelizumab (6) · Fluzoparib (5) · Famitinib (5) · Trastuzumab rezetecan (4)
Studies
Open first, then newest update. How each study uses dalpiciclib is read from its arms, and is right about nine times in ten.
Testing it · 67
- Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast CancerNot yet recruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07892274Written as Dalpiciclib
- IN10018 in Combination With Dalpiciclib for Progressive MeningiomasRecruitingPhase 1Capital Medical UniversityNCT07652762Written as Dalpiciclib
- Dalpicilib-Enhanced vs. Standard Endocrine Therapy in ER+ HER2- Early Breast CancerRecruitingPhase 3Fudan UniversityNCT06637150Written as Dalpicilib
- Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast CancerNot yet recruitingNot applicableHenan Cancer HospitalNCT07706933Written as Dalpiciclib
- Precision Medicine for Immunotherapy-Resistant Advanced Esophageal CancerNot yet recruitingPhase 2/3Peking University Cancer Hospital & InstituteNCT07653451Written as Dalpiciclib + Pyrotinib
- Neoadjuvant Dalpiciclib + AI → SHR-A1811 for HR+/HER2-Low Breast CancerNot yet recruitingPhase 2Tang-Du HospitalNCT07618923Written as Dalpiciclib 125mg
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingPhase 2Fudan UniversityNCT05582499Written as Dalpiciclib
- Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast CancerRecruitingPhase 2Sun Yat-sen UniversityNCT07610720Written as Dalpiciclib
- Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical StudyRecruitingPhase 2Fujian Cancer HospitalNCT07581834Written as Dalpiciclib 125mg
- Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain MetastasesNot yet recruitingPhase 2Nanfang Hospital, Southern Medical UniversityNCT07539753Written as Dalpiciclib
- Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast CancerEnrolling by invitationPhase 2Peking UniversityNCT06650748Written as Dalpiciclib
- Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line TreatmentRecruitingPhase 3Fujian Cancer HospitalNCT07467330Written as dalpiciclib + capecitabine + endocrine therapy
- Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）RecruitingPhase 2Hebei Medical University Fourth HospitalNCT06107673Written as Dalpiciclib
- Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II StudyNot yet recruitingPhase 2Fudan UniversityNCT07179939Written as Dalpiciclib
- Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 InhibitorNot yet recruitingPhase 2Beijing 302 HospitalNCT06556862Written as Dalpiciclib
- Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage PatientsNot yet recruitingPhase 2Fujian Cancer HospitalNCT07101159Written as Dalpiciclib
- The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant TreatmentNot yet recruitingNot applicableHongmei Zheng, PhDNCT06810492Written as Ribociclib; abemaciclib; palbociclib; Dalpiciclib
- Albumin-bound Paclitaxel、Dalpiciclib and AI in ER-Low (1%-10%) HER2-ABCNot yet recruitingNot applicableFujian Medical UniversityNCT06711094Written as Dalpiciclib
- Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell CarcinomaRecruitingPhase 2Peking UniversityNCT06684600Written as Dalpiciclib + Pyrotinib
- SNF Platform Study of HR+/ HER2-advanced Breast CancerRecruitingPhase 2Fudan UniversityNCT05594095Written as Dalpiciclib
See all 67 studies that test dalpiciclib →
Given in every arm · 10 — dalpiciclib is usual care beside what is tested
- Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast CancerRecruitingPhase 2Hebei Medical University Fourth HospitalNCT07492394Written as Dalpiciclib
- A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.RecruitingPhase 3Risen (Suzhou) Pharma Tech Co., Ltd.NCT07207070Written as Dalpiciclib
- Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast CancerRecruitingPhase 2wanghaiboNCT07285382Written as Dalpiciclib 125mg
- Darxicilib Combined With Abiraterone Acetate Tablets (II) for the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer.Not yet recruitingPhase 2Qilu Hospital of Shandong UniversityNCT06500247Written as Dalpicilib
- Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast CancerRecruitingPhase 2Fudan UniversityNCT05949541Written as CDK4/6 Inhibitor SHR6390
- PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast CancerRecruitingPhase 2Fudan UniversityNCT05759546Written as Dalpiciclib
- Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast CancerActive, not recruitingPhase 2Fudan UniversityNCT05759572Written as Dalpiciclib
- Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast CancerActive, not recruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT05463601Written as dalpiciclib
- PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast CancerActive, not recruitingPhase 3Zhimin ShaoNCT06612814Written as Dalpiciclib
- A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast CancerStatus unknownPhase 2Jinming YuNCT04095390Written as SHR6390
Codes
What other systems call dalpiciclib · ClinicalTrials.gg INT001771
- MeSH (NLM) C000720752dalpiciclibOne source NLM
- UNII (FDA) 5ZHA5P4PFXDALPICICLIBConfirmed FDA, NLM, Wikidata
- Wikidata Q125451978dalpiciclibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C125899DalpiciclibOne source FDA
- DrugBank DB17456One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000720752 | dalpiciclib | One source NLM |
| UNII (FDA) | 5ZHA5P4PFX | DALPICICLIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q125451978 | dalpiciclib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C125899 | Dalpiciclib | One source FDA |
| DrugBank | DB17456 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.